Cardiogeni Plc

About Cardiogeni Plc

Founded by Nobel Laureate, Professor Sir Martin Evans, the Cardiogeni Group is developing a new class of life-saving cellular medicines. The Group’s platform technology enables the creation of unique (living) cells that are engineered with a therapeutic function. The Group’s lead product, CLXR-001, is a patented engineered cellular medicine to treat heart failure patients which is administered during coronary artery bypass grafting surgery.The Group’s novel technology was developed in-house by Professor Sir Martin Evans and is protected by a portfolio of ~100 international patents and trademarks. CLXR-001 targets heart failure and consists of a novel allogeneic (off-the-shelf) cell type, iMP cells, engineered for cardiac regeneration, which will affect 1 in 4 people in their lifetime and is not reversible or curable. This technology is expected to regenerate the damaged heart tissue restoring heart function and improving life expectancy and quality of life. CLXR-001 has successfully completed an EU Phase II clinical trial in which patients showed a statistically significant (P<0.05) improvement in all parameters including heart function, reduction in heart scarring and an improvement in quality of life.